Qualification Advantages
Hibisure has independent research and development, manufacturing, and quality inspection departments, and its products have successively obtained registration and certification from China's CFDA, EU CE, and US FDA.
About Us
Focusing on the continuous innovation of diagnostic and treatment technologies for sleep breathing disorders and respiratory diseases, Hibisure provides high-quality products and services for global users in the fields of pulmonary function testing, non-invasive ventilation, oxygen therapy, and inhalation drug delivery.
Headquartered in Suzhou Science and Technology City, Hibisure has set up two production bases in Wuzhong, Suzhou and Jiangning, Nanjing, with a complete R&D, production and service system and independent laboratories, manufacturing department and quality inspection department. Our products have successively obtained the registrations and certificates of NMPA, CE, and FDA, and we have also accumulated a number of patents, trademarks, and software copyrights around the globe.
Relying on BiSure call network health management system,Hibisure will carry out digital management of the whole disease process around the different stages of diagnosis, treatment and rehabilitation of respiratory diseases, and provide more humane technical services and health care for every user.
100+ 70,000 sqft 1,000,000+pics
Employees Manufacturing plant Annual sales
Development History
2017Year3Month
Found in Suzhou
Patent for Total Respiratory Drug Delivery System filed via PCT in 2016;
Invested by Suzhou High-Tech Investment Group in December 2017.
2019Year5Month
Launched the BN series products
BNs launched for inhalation therapy of lower respiratory tract and sinusitis
2022Year12Month
Million units milestone
Annual domestic and overseas sales exceeded 1,000,000 units for the first time;
Added 65,000 square feet of production base in Jiangning District, Nanjing.
2023Year5Month
Launched the BO and BV series products
BOs launched for oxygen therapy;
BVs launched for OSAS and COPD.
2024Year12Month
BOV products enter clinical trials
Product combining BO, BV core functions enters clinical trials.
